07/05/21 -"Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported better-than-expected sales in Q1 21. Higher revenue trickled down and ..."
Pages
49
Language
English
Published on
07/05/21
You may also be interested by these reports :
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...